Review surveys headache targets beyond CGRP, including early endocannabinoid…
Novel targets in headache: A narrative review.
AI Summary
This narrative review asks what therapeutic targets beyond calcitonin gene-related peptide (CGRP) might help prevent or treat headache disorders. It synthesizes preclinical and clinical research on emerging targets; it is not a single trial, and the abstract reports no pooled quantitative results. CGRP-targeted treatments are also being explored for headache disorders beyond migraine, while the review notes that many people with migraine still lack adequate relief.
The review highlights pituitary adenylate cyclase-activating peptide (PACAP), for which it reports supportive preclinical evidence and two phase 2 trials showing preventive efficacy of a PACAP antibody in migraine. It also describes the endocannabinoid system as having antinociceptive potential, especially through effects on cannabinoid receptors and enzymes that break down endocannabinoids. Other targets—including prolactin, orexin-2 receptors, protease-activated receptor-2, and peroxynitrite—are at varying stages of research. Because this is a narrative review, the abstract cannot establish how effective or safe these approaches are overall, or whether endocannabinoid-based treatments benefit patients; this is an abstract-based summary, not a review of the full text.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Endocannabinoid research papers you might find interesting.
Meta-analysis finds shared endocannabinoid gene changes across myopathies
Small biomarker analysis finds no significant changes after 10 HBOT sessions
Rat study finds mixed behavioral and biological effects of WIN under chronic…
Explore More Research
Stay informed about the latest cannabis science.